Patients with obesity who have type 1 diabetes are suboptimally treated for their obesity because doctors were unclear how effective the medications would be for obesity and because there were concerns regarding the risks pertaining to their type 1 diabetes, Ebaa Al Ozairi , MD, chief medical officer and head of clinical research and clinical trials at Dasman Diabetes Institute in Kuwait, and Carel le Roux, MD, PhD , professor at Ulster University School of Medicine in the U.K., told Healio
doi: 10.1093/jsxmed/qdae182
Tirzepatide is a once weekly subcutaneous injection
Can BPC-157 heal leaky gut
After an injury ended his Navy SEAL training, he shifted to personal training, discovered functional lab testing, and became a leading expert in metabolic health